Composition: Human fibrinogen 1g
Indication: FIBRYGA is used for the treatment of bleeding in patients with congenital lack of fibrinogen (hypo- or afibrinogenaemia) with a bleeding tendency. It is also used for fibrinogen supplementation in patients with uncontrolled severe bleeding accompanied by acquired lack of fibrinogen.
Composition: Human Recombinant Coagulation Factor VIII 500IU Indication: Nuwiq contains the active substance human recombinant coagulation factor VIII (simoctocog alfa). Factor VIII is necessary for the blood to form clots and stop bleeding. In patients with hemophilia A (inborn factor VIII deficiency), factor VIII is missing or not working properly. Nuwiq replaces the missing factor Vlll and is used for treatment and prevention of bleeding in patients with hemophilia A and can be used for all age groups
Composition: Human immunoglobulin 10% (5g in 50ml)
Indication: Replacement therapy in primary immunodeficiency syndromes, Myeloma or chronic lymphatic leukemia with severe secondary hypogammaglobulinemia and recurrent infections and children with congenital AIDS and recurrent bacterial infections. Also has Immunomodulatory effect in Idiopathic thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, Guillain Barré syndrome, Kawasaki disease, Allogeneic bone marrow transplantation.
Composition: Human coagulation factor VIII 1000IU
Indication: Treatment and prevention of bleeding episodes in patients with hemophilia A (congenital or acquired FVIII deficiency), including previously treated patients (PTPs), previously untreated patients (PUPs) and patients undergoing major and minor surgical procedures; and for the treatment of inhibitors by Immune Tolerance Induction (ITI).
Composition: Human coagulation factor VIII 250IU
Indication: Treatment and prevention of bleeding episodes in patients with hemophilia A (congenital or acquired FVIII deficiency), including previously treated patients (PTPs), previously untreated patients (PUPs) and patients undergoing major and minor surgical procedures; and for the treatment of inhibitors by Immune Tolerance Induction (ITI).
Composition: Human coagulation factor VIII 500IU Indication: Treatment and prevention of bleeding episodes in patients with hemophilia A (congenital or acquired FVIII deficiency), including previously treated patients (PTPs), previously untreated patients (PUPs) and patients undergoing major and minor surgical procedures; and for the treatment of inhibitors by Immune Tolerance Induction (ITI).
Composition: Human Coagulation Factor IX 500IU Indication: Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Composition: Human prothrombin complex concentrate containing Factors II, VII, IX, X, as well as the inhibitor, protein C, and its cofactor protein S. Indication: Octaplex is used to treat and prevent bleeding caused by medicines called vitamin K antagonists (such as warfarin). Octaplex is used when rapid correction of the shortage is required in people born with a shortage of the vitamin K dependent clotting factors II and X. It is used when purified specific clotting factor product is not available.
Composition: 500 IU von Willebrand factor and 500 IU factor VIII Indication: Wilate belongs to the pharmacotherapeutic group of medicines called cloning factors and contains human blood coagulation factor VIII (FVIII) and von Willebrand factor (VWF). Together these two proteins are involved in blood clotting. Wilate is used to treat and prevent bleeding in patients with van Willebrand disease (VWD), which in fact is a family of related diseases. All types of W/0 are inborn. where bleeding can go on for longer than expected. This is either due to a lack of WIF in the blood or due to WJF that does not work the way it should. Wilate is used to treat and prevent bleeding in patients with hemophilia A. This is a condition in which bleeding can go on for longer than expected. It is due to an inborn lack of FVIII in the blood.
